Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer

NCT00234403 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00234403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00234403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
October 31, 2007
Enrollment
60
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer